The new 2025 Eltrombopag/Eltrombopag medical insurance reimbursement policy is released, come and take a look!

Eltrombopag/Eltrombopag is a drug used to treat thrombocytopenia and has received widespread attention in the Chinese market in recent years. As an original drug, Eltrombopag entered the country under the name of Eltrombopag ethanolamine tablets and has been included in Class B medical insurance. Recently, the introduction of new medical insurance reimbursement policies for Eltrombopag has triggered heated discussions among patients and the medical community.

According to the latest medical insurance policy, the reimbursement scope of Eltrombopag is mainly for patients with specific indications. First, eligible patients include adults who have previously had poor response to treatments such as glucocorticoids and immunoglobulins, as well as patients aged 6 years and older with chronic immune (idiopathic) thrombocytopenia (ITP). In addition, patients with severe aplastic anemia (SAA) can also obtain medical insurance reimbursement for eltrombopag if they have insufficient relief after previous immunosuppressive treatment. The introduction of this policy is undoubtedly a major good news for patients who meet these specific conditions, because it will reduce their financial burden and enable more patients to receive necessary treatment.

In practical applications, Eltrombopag has two common specifications in China: 25mg 14 tablets and 25mg 28 tablets, with prices ranging from RMB 2,000 to RMB 4,000. Although it has been included in medical insurance, patients still need to note that only patients who meet the above indications can enjoy medical insurance reimbursement. For those patients who are not eligible, they may need to bear the entire cost themselves, which is a heavy burden for some patients with poor financial conditions. Therefore, patients must fully communicate with professional doctors before using eltrombopag to ensure that their situation meets the reimbursement standards of medical insurance.

Reference materials:https://go.drugbank.com/drugs/DB06210